Alyeska Investment Group, L.P. Ascendis Pharma A/S Transaction History
Alyeska Investment Group, L.P.
- $25 Billion
- Q4 2024
A detailed history of Alyeska Investment Group, L.P. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 155,000 shares of ASND stock, worth $23.7 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
155,000
Previous 115,000
34.78%
Holding current value
$23.7 Million
Previous $17.2 Million
24.25%
% of portfolio
0.09%
Previous 0.1%
Shares
11 transactions
Others Institutions Holding ASND
# of Institutions
236Shares Held
60.2MCall Options Held
80.3KPut Options Held
216K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.55 Billion22.55% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.53MShares$847 Million3.52% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.1MShares$781 Million10.24% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.45MShares$682 Million0.98% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$671 Million0.32% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.55B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...